China

Hansoh Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib

Lead Product(s): Almonertinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: EQRx

Deal Size: Undisclosed Upfront Cash: $100.0 million

Deal Type: Licensing Agreement July 23, 2020

Details:

Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).

Antengene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commerciali...

Lead Product(s): Selinexor,Dexamethasone

Therapeutic Area: Oncology Product Name: ATG-010

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Fidelity Management & Research Company

Deal Size: $97.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing July 21, 2020

Details:

Proceeds from the Series C financing will be primarily used to fund the continuing clinical development of Antengene's robust pipeline of hematology and oncology therapies, expanding in-house R&D capabilities and strengthening the commercial infrastructures in APAC markets.

BeiGene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Amgen Doubles Down on BeiGene Collaboration, Investing $421M More

Lead Product(s): Denosumab

Therapeutic Area: Oncology Product Name: Xgeva

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Amgen Inc

Deal Size: $2,800.0 million Upfront Cash: Undisclosed

Deal Type: Investment July 12, 2020

Details:

This additional investment reflects Amgen's confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world's second largest pharmaceutical market.

PHARMAESSENTIA CORP

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

U.S. FDA Accepts PharmaEssentia’s Application for Ropeginterferon Alfa-2b to Treat Polythycemia Vera

Lead Product(s): Ropeginterferon ALFA-2B

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

The filing is supported by robust, durable 24-36-month data from the Phase 3 PROUD/CONTI-PV clinical trial showing high & durable hematologic responses and symptom control with good tolerability and low rates of depression, with effects on relevant MPN mutations.

BeiGene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BeiGene Gets Approval for BRUKINSA in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Two more Indications

Lead Product(s): Zanubrutinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2020

Details:

BTK inhibitor BRUKINSA™ (zanubrutinib) has received approval from the China NMPA in 2 indications: chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least one prior therapy, and mantle cell lymphoma who have received at least one prior therapy.

Zai Lab

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Lead Product(s): Optune

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate.

CStone Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CStone Gets NMPA Acceptance of its New Drug Application in Mainland China for Avapritinib in Two Gastrointestinal Stromal Tumor Indications

Lead Product(s): Avapritinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

Avapritinib has demonstrated outstanding antitumor activity and a well-tolerated safety profile in advanced PDGFRA exon 18 mutant GIST and fourth-line GIST.

CStone Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Cstone Submits New Drug Application for the Targeted Therapy Avapritinib In Taiwan

Lead Product(s): Avapritinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 27, 2020

Details:

Data demonstrated an ORR of 84% with most adverse events reported as Grade 1 or 2 for avapritinib in patients with advanced GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Hansoh Pharma

Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib

Antengene

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commerciali...

BeiGene

Amgen Doubles Down on BeiGene Collaboration, Investing $421M More

PHARMAESSENTIA CORP

U.S. FDA Accepts PharmaEssentia’s Application for Ropeginterferon Alfa-2b to Treat Polythycemia Vera

BeiGene

BeiGene Gets Approval for BRUKINSA in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Two more Indications

Zai Lab

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

CStone Pharmaceuticals

CStone Gets NMPA Acceptance of its New Drug Application in Mainland China for Avapritinib in Two Gastrointestinal Stromal Tumor Indications

CStone Pharmaceuticals

Cstone Submits New Drug Application for the Targeted Therapy Avapritinib In Taiwan